Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
$0.95
+6.7%
$0.98
$0.73
$11.90
$20.58M0.52117,231 shs137,854 shs
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
$0.79
+3.9%
$1.08
$0.71
$8.20
$43.45M2.331.66 million shs822,493 shs
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
$17.57
+3.7%
$23.19
$5.67
$30.99
$875.51M1.64999,300 shs942,971 shs
Fluidigm Co. stock logo
FLDM
Fluidigm
$3.66
$2.67
$7.51
$283.76M1.14968,838 shs60,126 shs
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
$3.72
+0.5%
$4.29
$3.60
$6.29
$161.45M1.4285,588 shs92,086 shs
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
+3.31%+1.42%-10.36%-33.78%-87.14%
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
+1.41%-12.57%-26.87%-42.38%-88.78%
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
-3.97%-20.35%-23.85%-31.96%+88.33%
Fluidigm Co. stock logo
FLDM
Fluidigm
0.00%0.00%0.00%0.00%0.00%
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
0.00%-16.67%-11.27%-19.74%-24.34%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
2.9174 of 5 stars
1.33.00.04.72.42.50.6
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
2.0701 of 5 stars
3.33.00.00.02.60.01.3
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
2.1866 of 5 stars
3.51.00.00.02.74.20.0
Fluidigm Co. stock logo
FLDM
Fluidigm
N/AN/AN/AN/AN/AN/AN/AN/A
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
3.0161 of 5 stars
2.04.00.04.51.81.70.0

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
2.50
Moderate Buy$1.005.26% Upside
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
2.67
Moderate Buy$21.332,585.46% Upside
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
3.00
Buy$34.0093.51% Upside
Fluidigm Co. stock logo
FLDM
Fluidigm
N/AN/AN/AN/A
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
N/AN/A$7.0088.17% Upside

Current Analyst Ratings

Latest BNGO, AXDX, FLDM, EYPT, and HBIO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/2/2024
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
4/1/2024
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$2.00 ➝ $1.00
3/7/2024
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Outperform ➝ Sector Outperform$7.00 ➝ $6.00
2/16/2024
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
Capital One Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight
2/16/2024
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$30.00 ➝ $39.00
(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
$12.06M1.71N/AN/A($1.37) per share-0.69
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
$36.12M1.20N/AN/A$2.10 per share0.38
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
$46.02M19.02N/AN/A$5.66 per share3.10
Fluidigm Co. stock logo
FLDM
Fluidigm
$130.58M0.00N/AN/A$1.24 per share0.00
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
$112.25M1.44$0.23 per share16.19$1.71 per share2.18

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
-$61.62M-$4.89N/AN/AN/A-454.95%N/A-170.54%5/9/2024 (Estimated)
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
-$232.49M-$6.62N/AN/AN/A-643.74%-103.68%-71.45%5/14/2024 (Estimated)
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
-$70.79M-$1.83N/AN/AN/A-153.84%-61.48%-33.49%5/1/2024 (Estimated)
Fluidigm Co. stock logo
FLDM
Fluidigm
-$59.24M-$0.78N/AN/AN/A-45.36%-40.15%-14.86%N/A
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
-$3.41M-$0.08N/AN/A-3.04%2.75%1.45%4/23/2024 (Estimated)

Latest BNGO, AXDX, FLDM, EYPT, and HBIO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/23/2024N/A
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
N/A$0.02+$0.02N/AN/AN/A
3/28/2024Q4 2023
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
-$0.62-$0.89-$0.27-$0.89$3.80 million$3.03 million
3/7/202412/31/2023
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
-$0.60-$0.33+$0.27-$0.33$8.71 million$14.03 million  
3/7/2024Q4 2023
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
$0.03$0.01-$0.02$0.06$27.80 million$28.15 million
3/5/2024Q4 2023
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
N/A-$0.96-$0.96-$0.96N/A$10.72 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
N/AN/AN/AN/AN/A
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
N/AN/AN/AN/AN/A
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
N/AN/AN/AN/AN/A
Fluidigm Co. stock logo
FLDM
Fluidigm
N/AN/AN/AN/AN/A
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
N/A
2.03
1.76
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
0.04
1.40
1.17
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
N/A
5.45
5.39
Fluidigm Co. stock logo
FLDM
Fluidigm
0.68
1.45
1.03
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
0.42
1.85
0.92

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
17.14%
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
11.35%
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
99.41%
Fluidigm Co. stock logo
FLDM
Fluidigm
76.59%
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
80.87%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
17921.66 million12.22 millionOptionable
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
34454.69 million53.36 millionOptionable
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
12149.83 million43.33 millionOptionable
Fluidigm Co. stock logo
FLDM
Fluidigm
61576.49 million74.27 millionOptionable
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
39143.40 million39.49 millionOptionable

BNGO, AXDX, FLDM, EYPT, and HBIO Headlines

SourceHeadline
Watch These 5 Technology Stocks for Q1 Earnings: Beat or Miss?Watch These 5 Technology Stocks for Q1 Earnings: Beat or Miss?
zacks.com - April 22 at 12:46 PM
Harvard Bioscience (HBIO) Set to Announce Earnings on TuesdayHarvard Bioscience (HBIO) Set to Announce Earnings on Tuesday
marketbeat.com - April 22 at 7:35 AM
Harvard Counselor Upholds "Standard Procedure" Amid $20M Wrongful Death Suit, Lacks Tang Follow-Up ConfirmationHarvard Counselor Upholds "Standard Procedure" Amid $20M Wrongful Death Suit, Lacks Tang Follow-Up Confirmation
hoodline.com - April 19 at 9:59 AM
Harvard Residential Advisers Allege University Administrators Engaged in Union-Busting TacticsHarvard Residential Advisers Allege University Administrators Engaged in Union-Busting Tactics
thecrimson.com - April 19 at 9:59 AM
The Harvard Public Opinion Project: Meet the Students Running the Annual Youth PollThe Harvard Public Opinion Project: Meet the Students Running the Annual Youth Poll
msn.com - April 19 at 9:59 AM
Harvard, Stanford and MIT get an F from ADL on antisemitism report cardHarvard, Stanford and MIT get an 'F' from ADL on antisemitism report card
msn.com - April 18 at 11:09 PM
Readers agree: Harvard is right to bring back standardized testsReaders agree: Harvard is right to bring back standardized tests
boston.com - April 18 at 11:09 PM
Harvard Law Faculty Letter Calls for Protection of Speech From Administrative ActionHarvard Law Faculty Letter Calls for Protection of Speech From Administrative Action
thecrimson.com - April 18 at 11:09 PM
Harvard Poll of Young Voters Finds Biden with Wide Lead Over Trump, But Just 9% Think Country Is Moving in Right DirectionHarvard Poll of Young Voters Finds Biden with Wide Lead Over Trump, But Just 9% Think Country Is Moving in Right Direction
msn.com - April 18 at 11:09 PM
Three things that should worry Democrats in new Harvard poll. And one for Republicans | AnalysisThree things that should worry Democrats in new Harvard poll. And one for Republicans | Analysis
masslive.com - April 18 at 11:09 PM
Design School Student Gov. Urges Harvard to Divest From ‘Illegal Occupation of Palestine’Design School Student Gov. Urges Harvard to Divest From ‘Illegal Occupation of Palestine’
thecrimson.com - April 18 at 11:09 PM
Short Interest in Harvard Bioscience, Inc. (NASDAQ:HBIO) Decreases By 11.1%Short Interest in Harvard Bioscience, Inc. (NASDAQ:HBIO) Decreases By 11.1%
marketbeat.com - April 16 at 6:31 PM
Harvard Bioscience (NASDAQ:HBIO) Shares Pass Below 200 Day Moving Average of $4.50Harvard Bioscience (NASDAQ:HBIO) Shares Pass Below 200 Day Moving Average of $4.50
americanbankingnews.com - April 16 at 3:14 AM
Harvard Bioscience to implement $4M in layoffsHarvard Bioscience to implement $4M in layoffs
wbjournal.com - April 12 at 3:40 PM
Harvard Bioscience, Inc.: Harvard Bioscience Announces Action to Improve Operational Efficiency and Support Ongoing Investments in GrowthHarvard Bioscience, Inc.: Harvard Bioscience Announces Action to Improve Operational Efficiency and Support Ongoing Investments in Growth
finanznachrichten.de - April 9 at 2:39 PM
Harvard Bioscience Announces Action to Improve Operational Efficiency and Support Ongoing Investments in GrowthHarvard Bioscience Announces Action to Improve Operational Efficiency and Support Ongoing Investments in Growth
globenewswire.com - April 9 at 9:00 AM
Women’s softball defeats Harvard 2-0 on SundayWomen’s softball defeats Harvard 2-0 on Sunday
browndailyherald.com - April 3 at 11:51 PM
Harvard man pleads guilty to assaultHarvard man pleads guilty to assault
news.yahoo.com - April 3 at 6:50 PM
Chappell Roan Lectured at Harvard and Kissed Olivia Rodrigo All in One DayChappell Roan Lectured at Harvard and Kissed Olivia Rodrigo All in One Day
msn.com - April 3 at 6:50 PM
Uncovering Controversy: Harvard University Removes 19th-Century Book Bound with Human Skin From LibraryUncovering Controversy: Harvard University Removes 19th-Century Book Bound with Human Skin From Library
msn.com - April 3 at 1:49 PM
Harvard team engineers shape-shifting metafluid that can program robotsHarvard team engineers shape-shifting metafluid that can program robots
msn.com - April 3 at 1:49 PM
Eagles Defeat Harvard 17–9 in Dominant Last Three InningsEagles Defeat Harvard 17–9 in Dominant Last Three Innings
bcheights.com - April 3 at 3:48 AM
Biden National Security Official Discusses AI and Cybersecurity at Harvard Law School TalkBiden National Security Official Discusses AI and Cybersecurity at Harvard Law School Talk
thecrimson.com - April 3 at 3:48 AM
50 of the best Harvard University courses you can take online for free50 of the best Harvard University courses you can take online for free
msn.com - April 3 at 3:48 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Accelerate Diagnostics logo

Accelerate Diagnostics

NASDAQ:AXDX
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. The company was incorporated in 1982 and is headquartered in Tucson, Arizona.
Bionano Genomics logo

Bionano Genomics

NASDAQ:BNGO
Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA. The company also provides Saphyr and Bionano compute servers; and VIA software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.
EyePoint Pharmaceuticals logo

EyePoint Pharmaceuticals

NASDAQ:EYPT
EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
Fluidigm logo

Fluidigm

NASDAQ:FLDM
Fluidigm Corporation creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. Fluidigm Corporation has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.
Harvard Bioscience logo

Harvard Bioscience

NASDAQ:HBIO
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.